Another pivotal trial investigating the efficacy of ICI/VEGF combination therapy was CheckMate 9ER, a phase 3 study that assessed the efficacy of combination therapy with nivolumab and cabozantinib compared to sunitinib in previously untreated patients with advanced ccRCC [24]. Here, VEGFA is linked to nonpapillary renal cell carcinoma.